Time: 9:00 AM (PST), 12:00 PM (EST), 6:00 PM (CET)
Abstract
Discover the latest innovations in cervical cancer prevention and molecular diagnostics. This event will showcase cutting-edge advancements in integrated molecular automation and innovative assay design, with a specific focus on transforming screening practices through HPV self-collection in healthcare settings and extended genotyping designed to enhance risk assessment.
Learning Objectives:
Insightful Presentations: Learn from an industry leader about the impact of integrated molecular automation on laboratory efficiency and throughput.
Innovative Assay Design: Explore the capabilities of the BD Onclarity™ HPV Assay, the first FDA-approved test for extended genotyping, designed to provide comprehensive risk assessment.
Addressing Barriers: Understand how expanded HPV self-collection is improving screening access and patient engagement, reshaping cervical cancer screening paradigms.
Secure Your Spot:
Don't miss this opportunity to be at the forefront of transformative technologies driving the future of cervical cancer screening. Register now to join us as we shape the next era of healthcare together!
Webinars will be available for unlimited on-demand viewing after live event.
Even in the most controlled labs, balance performance can drift — electrostatics, air drafts, temperature shifts, or even the way samples are handled can quietly undermine your results...
Unlock the full potential of your LC-MS system with Thermo Scientific™ Chromeleon™ software features. This webinar will demonstrate the system suitability test with intelligent r...
Research in plant and animal genomics often involve complex genetic challenges that require tailored approaches. From addressing genetic complexity in aquaculture species to investigating tr...
Do you use pipettes in your daily work? Want to improve your pipetting accuracy? To eliminate the guesswork, METTLER TOLEDO Rainin developed Good Pipetting Practice™ (GPP™) as a...
BACKGROUND . Myelodysplastic syndromes (MDS) are a heterogeneous group of myeloid neoplasms with variable clinical outcomes and an increased risk of progression to Acute Myeloid Leukemia (AM...